Immunohistochemical Expression of Hepatocyte Growth Factor Receptor and Epidermal Growth Factor Receptor in Serous Ovarian Tumors. | ||||
| Zagazig University Medical Journal | ||||
| Article 21, Volume 31, Issue 3, March 2025, Page 1197-1209 PDF (1.44 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/zumj.2025.350021.3777 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Raghda mahdi Elarini  1; Eman Taher Nour Elden2; Reham Sameh2; Nelly Mohamed Said 2
| ||||
| 1pathology department faculty of medicine Zagazig university Egypt | ||||
| 2pathology department faculty of medicine zagazig university | ||||
| Abstract | ||||
| Background: Ovarian cancer mostly shows no symptoms and discovered at advanced stages, so high mortality is expected. Therefore, is considered a highly lethal gynecological cancer in women. More improvement could be achieved if there were sensitive and specific biomarkers for the disease in the early stages. We aimed to evaluate the correlation between the expression of Hepatocyte Growth Factor Receptor (HGFR) and Epidermal Growth Factor Receptor (EGFR) in ovarian serous tumors and their relationship with pathological criteria. Methods: Seventy paraffin-embedded tissue blocks of ovarian serous tumors were included, and categorized as 20 benign, 25 borderline and 25 malignant tumors. HGFR and EGFR immunohistochemical staining was done. Results: Among benign tumors, negative HGFR was in 70% of benign tumors, and EGFR was negative in 60%. In borderline tumors, HGFR was positive in 76%, and EGFR was positive in 68%. All malignant tumors were positive for HGFR and EGFR. A substantially significant variations were found between HGFR expression and both grade and stage (P=0.006, P=0.009, respectively), and EGFR expression with grade and stage (P=0.004, P<0.001, respectively). HGFR had a significant positive correlation with EGFR expressions among all studied cases (r=0.846, P<0.001), with also a significant positive relationship between HGFR and EGFR regarding grade (r=0.544, P=0.005) (r=0.500, P=0.01), respectively, as well as stage (r=0.550, P=0.004), (r=0.778, P<0.001), respectively in malignant cases. Conclusions: HGFR and EGFR expressions are strongly overexpressed in ovarian serous carcinoma than borderline and benign tumors and correlated with poorer prognostic outcomes as higher grades and advanced disease stages. | ||||
| Keywords | ||||
| : Ovarian cancer; Serous tumors; Hepatocyte Growth Factor Receptor; Epidermal Growth Factor Receptor | ||||
|
Statistics Article View: 13,786 PDF Download: 45 |
||||
